Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial.

Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE

Publication: 2001- : London : BioMed Central Ltd.
Original Publication: London : Current Science Ltd., c2000-

Home Care Services, Hospital-Based*/trends; Exercise Therapy/*methods ; Positive-Pressure Respiration/*methods ; Pulmonary Disease, Chronic Obstructive/*psychology ; Pulmonary Disease, Chronic Obstructive/*therapy ; Quality of Life/*psychology; Adult ; Aged ; Exercise Therapy/trends ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Positive-Pressure Respiration/trends ; Pulmonary Disease, Chronic Obstructive/rehabilitation ; Respiratory Function Tests/trends

Background: The use of noninvasive intermittent positive pressure ventilation (NIPPV) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure remains controversial as long-term data are almost lacking. The aim was to compare the outcome of 2-year home-based nocturnal NIPPV in addition to rehabilitation (NIPPV + PR) with rehabilitation alone (PR) in COPD patients with chronic hypercapnic respiratory failure.
Methods: Sixty-six patients could be analyzed for the two-year home-based follow-up period. Differences in change between the NIPPV + PR and PR group were assessed by a linear mixed effects model with a random effect on the intercept, and adjustment for baseline values. The primary outcome was health-related quality of life (HRQoL); secondary outcomes were mood state, dyspnea, gas exchange, functional status, pulmonary function, and exacerbation frequency.
Results: Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)). Exacerbation frequency was not changed.
Conclusions: The addition of NIPPV to pulmonary rehabilitation for 2 years in severe COPD patients with chronic hypercapnic respiratory failure improves HRQoL, mood, dyspnea, gas exchange, exercise tolerance and lung function decline. The benefits increase further with time.
Trial Registration: ClinicalTrials.Gov (ID NCT00135538).

Am Rev Respir Dis. 1989 Nov;140(5):1251-6. (PMID: 2683904)
Thorax. 1995 Aug;50(8):824-8. (PMID: 7570431)
Ann Intern Med. 2009 Oct 20;151(8):517-27. (PMID: 19841453)
Eur Respir J. 2002 Sep;20(3):570-6. (PMID: 12358330)
Thorax. 2009 Jul;64(7):561-6. (PMID: 19213769)
Gerontologist. 1990 Aug;30(4):497-502. (PMID: 2394384)
Eur Respir J. 1998 Aug;12(2):363-9. (PMID: 9727786)
Thorax. 2002 Feb;57(2):116-9. (PMID: 11828039)
Thorax. 2010 Sep;65(9):765-7. (PMID: 20805166)
Eur Respir J. 2002 Jul;20(1):20-9. (PMID: 12166571)
Thorax. 1987 Oct;42(10):773-8. (PMID: 3321537)
JAMA. 1994 Nov 16;272(19):1497-505. (PMID: 7966841)
Thorax. 2010 Apr;65(4):303-8. (PMID: 20388753)
Eur Respir J. 1999 Jun;13(6):1293-300. (PMID: 10445604)
Control Clin Trials. 1989 Dec;10(4):407-15. (PMID: 2691207)
J Clin Epidemiol. 2003 Aug;56(8):752-9. (PMID: 12954467)
Biometrics. 1982 Dec;38(4):963-74. (PMID: 7168798)
J Cardiopulm Rehabil. 2006 Jan-Feb;26(1):44-53. (PMID: 16617228)
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1335-41. (PMID: 11029341)
Thorax. 2009 Jul;64(7):553-6. (PMID: 19561274)
Chest. 2007 Dec;132(6):1810-6. (PMID: 18079217)
Chest. 2000 Dec;118(6):1582-90. (PMID: 11115443)
Eur Respir J. 2002 Jul;20(1):12-9. (PMID: 12166558)
Acta Psychiatr Scand. 1983 Jun;67(6):361-70. (PMID: 6880820)
Ann Intern Med. 1995 Jun 1;122(11):823-32. (PMID: 7741366)
Respir Med. 2009 Sep;103(9):1329-36. (PMID: 19362809)
Respiration. 2011;81(3):242-6. (PMID: 21242669)
Eur Respir J. 2008 Aug;32(2):379-86. (PMID: 18385168)
Thorax. 2008 Dec;63(12):1052-7. (PMID: 18710905)
Chest. 2005 Aug;128(2):657-62. (PMID: 16100151)
Eur Respir J. 2002 Sep;20(3):529-38. (PMID: 12358325)
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003793. (PMID: 17054186)

ClinicalTrials.gov NCT00135538

Date Created: 20110825 Date Completed: 20120731 Latest Revision: 20240506

20240506

PMC3182911

10.1186/1465-9921-12-112

21861914